Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS.

Maricela ValerioCristina VeintimillaCarmen RodríguezSofía de la VillaMar Sánchez-SomolinosMónica Cerezales Carlos CrespoSara RodríguezIván AdanEsther ChamorroIrantzu RossellóPatricia Muñoz

Published in: Journal of medical economics (2023)

The economic impact of the management of these infections is high. The cost of dalbavancin is offset by the decreased length of stay.

Keyphrases

healthcare
combination therapy
acute care
replacement therapy
drug induced